Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Progression 60% Improvement Relative Risk Being in the hospitalized.. 41% c19zinc.com Bagheri et al. Zinc for COVID-19 Prophylaxis Favors zinc Favors control
Bagheri, 510 patient zinc prophylaxis study: 60% lower progression [p=0.41] and 41% lower hospitalization [p=0.37] https://c19p.org/bagheriz
copied to clipboard
Supplement Usage Pattern in a Group of COVID- 19 Patients in Tehran
Bagheri et al., Journal of Family & Reproductive Health, doi:10.18502/jfrh.v14i3.4668
1 Sep 2021    Source   PDF   Share   Tweet
Retrospective 510 patients in Iran, showing lower risk of severity with vitamin D (statistically significant) and zinc (not statistically significant) supplementation. IR.TUMS.VCR.REC.1398.1063.
risk of progression, 60.4% lower, OR 0.40, p = 0.41, treatment 33, control 477, adjusted per study, multinomial logistic regression, RR approximated with OR.
risk of being in the hospitalized vs. outpatient group, 41.0% lower, RR 0.59, p = 0.37, treatment 4 of 33 (12.1%), control 167 of 477 (35.0%), NNT 4.4, adjusted per study, odds ratio converted to relative risk, binary logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bagheri et al., 9/1/2021, retrospective, Iran, Middle East, peer-reviewed, 6 authors.
All Studies   Meta Analysis
This PaperZincAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit